Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,008.39 +18.06 (+1.82%)

Official Closing Price Updated: 7:00 PM EDT, Mar 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback? ↗

Today 14:20 EDT

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

Via The Motley Fool

Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock ↗

Today 12:20 EDT

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

Via The Motley Fool

The 2026 M&A Resurgence: Private Equity Confidence Hits Record Highs

Today 11:44 EDT

The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a...

Via MarketMinute

Eli Lilly & Co (NYSE:LLY) Emerges as a Prime GARP Investment Candidate ↗

March 07, 2026

Via Chartmill

Eli Lilly & Co (NYSE:LLY): A High-Growth Dividend Stock for Discerning Investors ↗

March 04, 2026

Via Chartmill

2 Top AI Healthcare Stocks to Buy and Hold ↗

Today 11:20 EDT

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

The Pivot to Legitimacy: Hims & Hers Health (HIMS) Faces a New Era of Personalized Medicine

Today 9:33 EDT

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most...

Via Finterra

Topics Artificial Intelligence Economy

Contrarian Take: Vanguard's 3 Worst-Performing Equity ETFs in 2026 Are All Buys in March ↗

Today 9:20 EDT

In a matter of months, last year's winners have shifted to losers, creating compelling buying opportunities for long-term investors.

Via The Motley Fool

Topics Artificial Intelligence ETFs

1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗

March 08, 2026

Eli Lilly may be the GLP-1 leader, but its valuation is stretched.

Via The Motley Fool

Topics Intellectual Property

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000 ↗

March 08, 2026

This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product.

Via The Motley Fool

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

These companies have a lot more to offer than their prospects in the weight loss market.

Via The Motley Fool

Topics Intellectual Property

Where Will Eli Lilly Stock Be in 10 Years? ↗

March 07, 2026

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Via The Motley Fool

Topics Intellectual Property

Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗

March 07, 2026

Things can't get that much worse for the drugmaker.

Via The Motley Fool

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? ↗

March 06, 2026

Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.

Via The Motley Fool

Tariffs News & Market Chaos ↗

March 06, 2026

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

Via The Motley Fool

Topics Economy Government World Trade

Here's How Much $1000 Invested In Eli Lilly 5 Years Ago Would Be Worth Today ↗

March 06, 2026

Via Benzinga

HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown ↗

March 06, 2026

The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories.

Via Stocktwits

Topics Earnings Lawsuit

Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗

March 05, 2026

Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.

Via The Motley Fool

The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026

March 05, 2026

As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Renovations and Equipment Upgrades Fell 18% in February 2026; Other Capital Projects Remain Stable

March 05, 2026

JACKSONVILLE BEACH, Fla., March 5, 2026 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads released its February 2026 Planned Capital Project Spending Report for the Industrial Manufacturing sector. The...

Via Send2Press

Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform ↗

March 05, 2026

Eli Lilly (NYSE: LLY) launches Employer Connect platform on March 5, 2026, offering Zepbound tirzepatide KwikPen at $449 across all doses to expand employer-sponsored obesity coverage.

Via Benzinga

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2026

Via StockStory

Topics Artificial Intelligence Intellectual Property

The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"

March 04, 2026

As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes

March 04, 2026

NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

S&P 500 to 7,800? Morgan Stanley Bets on "One Big Beautiful Act" and AI Productivity as Bears Warn of Bubble

March 04, 2026

As the first quarter of 2026 unfolds, the equity markets are at a historic crossroads. Morgan Stanley (NYSE:MS) has stunned Wall Street with a revised year-end target for the S&P 500, projecting the...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Eli Lilly Unusual Options Activity For March 04 ↗

March 04, 2026

Via Benzinga

Is Moderna Stock Outperforming the Dow?

March 04, 2026

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Via Barchart.com

Topics Stocks

Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗

March 04, 2026

The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro.

Via Stocktwits

Topics Lawsuit

2 Top Growth Stocks to Buy in the First Half of 2026 ↗

March 03, 2026

A decade from now, you might be very glad you did so.

Via The Motley Fool

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

March 03, 2026

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.